Recherche
-
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
(British Journal of Haematology. vol. 188, n° 6, pp. 935–944, 2020)Article de revue -
MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms
(BMC Cancer. vol. 18, n° 1, pp. 1098, 2018-12)Article de revue -
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study
(American Journal of Hematology. vol. 93, n° 4, pp. E84–E86, 2018-08)Article de revueAccès réservé -
Quantification of the Mutant CALR Allelic Burden by Digital PCR
(The Journal of Molecular Diagnostics. vol. 18, n° 1, pp. 68–74, 2016-01)Article de revue -
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
(Leukemia, 2020-07-21)Article de revue -
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
(Blood Advances. vol. 5, n° 5, pp. 1442-1451, 2021-03-09)Article de revue -
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
(Blood Cancer Journal. vol. 12, n° 4, pp. 56, 2022-04-08)Article de revueLibre accès -
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation
(Cancers. vol. 11, n° 12, 2019-12)Article de revueLibre accès -
Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms.
(Cancers. vol. 12, n° 9, 2020-08-28)Article de revueLibre accès -
JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens
(Leukemia & lymphoma. vol. 57, n° 8, pp. 1949–1951, 2016-08)Article de revue